Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 2Sarcoma, Synovial 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Liposarcoma 1Leiomyosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 10fludarabine 5Radiotherapy 5Doxorubicin 5Gemcitabine 3sargramostim 2fludarabine phosphate 2aldesleukin 2Sunitinib 2Radiation Dose Hypofractionation 2Nivolumab 2Leukapheresis 2Ifosfamide 2Docetaxel 2Decitabine 2Dacarbazine 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trofosfamide 1tremelimumab 1temsirolimus 1sotigalimab 1ribociclib 1poly ICLC 1pembrolizumab 1pegfilgrastim 1pazopanib 1pasireotide 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Synovial × sotigalimab × Clear all
NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Columbia University

Phase 2 Active not recruiting
27 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡